AVIR Atea Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AVIR

Price (delayed)

$3.96

Market cap

$333.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.63

Enterprise value

$191.87M

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding ...

Highlights
The debt has declined by 23% year-on-year and by 7% since the previous quarter
Atea Pharmaceuticals's quick ratio has decreased by 49% YoY and by 43% QoQ
Atea Pharmaceuticals's EPS has decreased by 17% YoY and by 3.2% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://ateapharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of AVIR
Market
Shares outstanding
84.16M
Market cap
$333.29M
Enterprise value
$191.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.6
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$134.94M
EBITDA
-$134.52M
Free cash flow
-$85.4M
Per share
EPS
-$1.63
Free cash flow per share
-$1.02
Book value per share
$6.65
Revenue per share
$0
TBVPS
$7.13
Balance sheet
Total assets
$594.97M
Total liabilities
$39.78M
Debt
$2.4M
Equity
$555.19M
Working capital
$558.08M
Liquidity
Debt to equity
0
Current ratio
18.24
Quick ratio
17.86
Net debt/EBITDA
1.05
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-22%
Return on equity
-23.1%
Return on invested capital
-31.4%
Return on capital employed
-24%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVIR stock price

How has the Atea Pharmaceuticals stock price performed over time
Intraday
3.39%
1 week
6.74%
1 month
1.54%
1 year
22.22%
YTD
29.84%
QTD
-1.98%

Financial performance

How have Atea Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$164.16M
Net income
-$135.96M
Gross margin
N/A
Net margin
N/A
The operating income is down by 26% YoY and by 4.2% QoQ
Atea Pharmaceuticals's net income has decreased by 17% YoY and by 3.6% from the previous quarter

Growth

What is Atea Pharmaceuticals's growth rate over time

Valuation

What is Atea Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.6
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Atea Pharmaceuticals's EPS has decreased by 17% YoY and by 3.2% QoQ
AVIR's P/B is 20% higher than its last 4 quarters average of 0.5
The company's equity fell by 13% YoY and by 4.6% QoQ

Efficiency

How efficient is Atea Pharmaceuticals business performance
AVIR's return on invested capital is up by 39% year-on-year but it is down by 6% since the previous quarter
The company's return on equity fell by 32% YoY and by 7% QoQ
The ROA has decreased by 31% YoY and by 6% QoQ

Dividends

What is AVIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVIR.

Financial health

How did Atea Pharmaceuticals financials performed over time
AVIR's total liabilities has soared by 52% YoY and by 51% from the previous quarter
The current ratio has declined by 49% year-on-year and by 43% since the previous quarter
The debt is 100% smaller than the equity
The debt has declined by 23% year-on-year and by 7% since the previous quarter
The company's equity fell by 13% YoY and by 4.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.